Patricia Nale, ELS

Fluctuating dry eye symptoms following surgery or exposure to environmental triggers are “highly suggestive” of flares, according to a poster presented at the Women in Ophthalmology Summer Symposium.

Three phase 3 studies of brolucizumab in patients with retinal diseases will be terminated early after more frequent dosing intervals were associated with higher rates of intraocular inflammation, Novartis announced.

WAILEA, Hawaii — Perfluorocarbon liquid represents “a big advance” in the surgical approach to subretinal fluid removal when performing vitrectomy for primary retinal detachment repair, Carl D. Regillo, MD, told colleagues at Retina 2021.

WAILEA, Hawaii — New research using liquid biopsy presents a new opportunity for treating retinoblastoma.

WAILEA, Hawaii — Dupilumab is an important treatment for patients with atopic dermatitis, but there can be ocular consequences, which themselves need treatment.

WAILEA, Hawaii — Considering bevacizumab was found to be noninferior to aflibercept with respect to visual acuity in the SCORE2 trial, the incremental cost-effectiveness ratio is “unfavorable,” Michael S. Ip, MD, said at Retina 2021.

WAILEA, Hawaii — Very few new adverse events related to the Port Delivery System device were seen in the 9 months following the primary endpoint of the Archway trial, according to a speaker here.

WAILEA, Hawaii — Retinal pigmentary changes were seen in 67% of patients in the phase 1/2 safety study of RGX-314, a gene therapy delivered subretinally for the treatment of AMD.

WAILEA, Hawaii — In patients with traumatic periorbital and orbital injuries, airway, breathing and circulation – the ABCs – need to be addressed first, before addressing ocular trauma.

WAILEA, Hawaii — While ophthalmologists internalize the lessons learned from the worst months of the pandemic in 2020, there is room for optimism that practice numbers are returning to pre-COVID levels.